Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8769095 | 0.87 | CA2 (0.71) | SMN1; SMN2CA2KMT2AGLA | |
| SCHEMBL7103984 | 0.86 | CTSK (0.60) | CA2NPC1RAB9A | |
| SCHEMBL8757522 | 0.85 | GLA (0.67) | SMN1; SMN2CA2KMT2AGLATAAR1 | |
| SCHEMBL14403609 | 0.83 | CTSS (0.65) | CA2KMT2A | |
| SCHEMBL8019170 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2AGLATAAR1NPC1 | |
| SCHEMBL7104136 | 0.79 | CYP2D6 (0.58) | KMT2A | |
| SCHEMBL5706137 | 0.78 | PPARG (0.51) | SMN1; SMN2KMT2AGLAPPARGPPARA | |
| SCHEMBL7904484 | 0.77 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AGLATAAR1NPC1 | |
| SCHEMBL12305803 | 0.76 | PPARA (0.64) | KMT2APPARGPPARAALDH1A1 | |
| SCHEMBL8239150 | 0.76 | PPARA (0.64) | KMT2APPARGPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140818-B1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMA INC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6329550-B1 | FOR THERAPY OF EMPHYSEMA, OSTEOPOROSIS, RHEUMATOID ARTHRITIS AND NEOPLASTIC DISEASES | AVENTIS PHARMACEUTICALS INC. | 2001-12-11 | — | — | US | disclosed |